Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 13/20 | 0.50 |
| ▸ | DRD4 | P21917 | 7/20 | 0.50 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 7/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9610941 | 0.80 | DRD3 (0.58) | DRD3DRD4EPHB3HDAC1DRD2 | |
| SCHEMBL6610807 | 0.80 | DRD3 (0.57) | DRD3DRD4EPHB3HDAC1DRD2 | |
| SCHEMBL22792160 | 0.77 | DRD3 (0.54) | DRD3DRD4EPHB3HDAC1DRD2 | |
| SCHEMBL29535086 | 0.77 | DRD3 (0.54) | DRD3DRD4EPHB3HDAC1DRD2 | |
| SCHEMBL16050082 | 0.77 | DRD3 (0.54) | DRD3DRD4EPHB3HDAC1DRD2 | |
| SCHEMBL6612386 | 0.77 | DRD3 (0.54) | DRD3DRD4EPHB3HDAC1DRD2 | |
| SCHEMBL1290470 | 0.75 | DRD3 (0.50) | DRD3DRD4EPHB3HDAC1DRD2 | |
| SCHEMBL23587071 | 0.74 | DRD3 (0.55) | DRD3DRD4EPHB3HDAC1DRD2 | |
| SCHEMBL3793301 | 0.74 | DRD3 (0.51) | DRD3DRD4EPHB3HDAC1DRD2 | |
| SCHEMBL1290838 | 0.74 | DRD3 (0.51) | DRD3DRD4EPHB3HDAC1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-08-21 | — | — | US | disclosed |
| US-20250171437-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-11919915-B2 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | AGIOS PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-2260020-B1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| EP-2260020-B1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| EP-2628726-A1 | Hydroxamate-based inhibitors of deacetylases b | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| EP-2628726-A1 | Hydroxamate-based inhibitors of deacetylases b | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8349883-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20110183964-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2011-07-28 | — | — | US | disclosed |
| US-7943652-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-7943652-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-7943652-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| EP-2260020-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG | 2009-10-01 | — | — | US | disclosed |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG | 2009-10-01 | — | — | US | disclosed |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG | 2009-10-01 | — | — | US | disclosed |
| WO-2009118305-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118305-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | DRD3 2953/4885DRD4 3751/4885EPHB3 3578/4885 |
| US-11919915-B2 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | PAH, KDM8, PHF8 | DRD3 2953/4885DRD4 3751/4885EPHB3 3578/4885 |
| US-20250171437-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | PAH, BCKDK, PKM | DRD3 3313/4885DRD4 3481/4885EPHB3 4337/4885 |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | HDAC1, HDAC11, HDAC3 | DRD3 3904/4885DRD4 4546/4885EPHB3 4272/4885 |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | DRD3 2953/4885DRD4 3751/4885EPHB3 3578/4885 |
| US-20110183964-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | HDAC1, HDAC11, HDAC3 | DRD3 3904/4885DRD4 4546/4885EPHB3 4272/4885 |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | DRD3 2953/4885DRD4 3751/4885EPHB3 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.